• S1 Episode 4: How Does the Gut Microbiome Impact Response to Cancer Therapy?

  • Nov 2 2022
  • Length: 22 mins
  • Podcast

S1 Episode 4: How Does the Gut Microbiome Impact Response to Cancer Therapy?

  • Summary

  • Drs Sumanta Pal and Jennifer Wargo discuss how the gut microbiome impacts response to cancer therapy in patients with renal cell carcinoma.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968742). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827966/

    The Microbiome in Cancer Immunotherapy: Diagnostic Tools and Therapeutic Strategies https://pubmed.ncbi.nlm.nih.gov/29567708/

    Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873287/

    Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721659/

    Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors https://pubmed.ncbi.nlm.nih.gov/29097494/

    Dietary Fiber and Probiotics Influence the Gut Microbiome and Melanoma Immunotherapy Response https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970537/

    Fiber in Diet Linked to Cancer Immunotherapy Response https://www.nih.gov/news-events/nih-research-matters/fiber-diet-linked-cancer-immunotherapy-response

    Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients https://www.science.org/doi/10.1126/science.abb5920

    Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients https://pubmed.ncbi.nlm.nih.gov/33542131/

    Fecal Microbiota for Transplantation: Safety Alert - Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission

    Fecal Microbiota Transplantation Followed by Anti–PD-1 Treatment in Patients With Advanced Melanoma https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9533

    Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma https://clinicaltrials.gov/ct2/show/NCT04940299

    Nivolumab plus Ipilimumab With or Without Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma: A Randomized Phase 1 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018425/

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about S1 Episode 4: How Does the Gut Microbiome Impact Response to Cancer Therapy?

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.